IO Biotech to Participate in Upcoming Investor Conferences
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company focused on developing innovative immune-modulating therapeutic cancer vaccines using the T-win platform, has announced that its senior management team will be participating in several upcoming investor conferences. These events will provide valuable insights into the company's current projects and future prospects.
Conference Details
At the Morgan Stanley 22nd Annual Global Healthcare Conference, Dr. Mai-Britt Zocca, the CEO of IO Biotech, will take part in a fireside chat on September 4, 2024, at 5:35 pm ET. This conference presents a significant opportunity for IO Biotech to engage with potential investors and share updates on the ongoing developments of their therapeutic offerings.
Participation in the H.C. Wainwright Conference
Following that, Amy Sullivan, the CFO of IO Biotech, will present the company’s strategic initiatives at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 10:30 am ET. This presentation aims to highlight the progress of IO Biotech's pipeline and its innovative approaches to cancer treatment.
Webcast Access
For those interested, a live webcast of these presentations will be available on IO Biotech's official website, allowing remote engagement with the content. After the events, the recordings will be accessible for about 90 days, enabling broader audience participation.
About IO102-IO103
IO102-IO103 is an experimental cancer vaccine designed to activate the immune system against both tumor cells and the immunosuppressive cells that hinder effective immune responses within the tumor microenvironment (TME). This pioneering therapy seeks to enhance T cell activation against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells, which are crucial targets in cancer therapy.
Clinical Trials and Collaborations
The clinical trials for IO102-IO103 are currently in critical phases. The company is conducting a Phase 3 trial (NCT05155254) that compares the vaccine in combination with pembrolizumab to pembrolizumab alone in patients with advanced melanoma. Additionally, a Phase 2 basket trial (NCT05077709) is underway to assess its effectiveness as a first-line treatment for various solid tumors, along with another Phase 2 study (NCT05280314) focusing on neo-adjuvant/adjuvant treatments. These studies are sponsored by IO Biotech in collaboration with Merck, which is providing pembrolizumab for the trials.
About IO Biotech
IO Biotech is an innovative clinical-stage biopharmaceutical company dedicated to developing immune-modulating cancer therapies. Their T-win platform offers a novel approach to cancer vaccine technology, leveraging the body’s immune response to target tumor-supportive cells. IO Biotech is advancing its lead candidate, IO102-IO103, through clinical trials while also assessing additional candidates at the preclinical stage.
Based on encouraging data from Phase 1/2 trials for metastatic melanoma, IO102-IO103 has been granted breakthrough therapy designation by the US Food and Drug Administration, enhancing its potential impact in the oncology field. IO Biotech operates globally, with its headquarters in Copenhagen and a significant presence in New York.
Contact Information
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
Email: mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Email: Julie.Funesti@salutemcomms.com
Frequently Asked Questions
What is the focus of IO Biotech?
IO Biotech specializes in developing immune-modulating therapeutic cancer vaccines.
When will IO Biotech present at investor conferences?
IO Biotech will participate in the Morgan Stanley Conference on September 4, 2024, and the H.C. Wainwright Conference on September 9, 2024.
How can I access the presentations from IO Biotech?
The webcast of the presentations will be available on IO Biotech's website for 90 days following the events.
What is IO102-IO103?
IO102-IO103 is an investigational therapeutic cancer vaccine targeting tumor cells and immune-suppressive cells in the tumor microenvironment.
Who are IO Biotech's collaborators for clinical trials?
IO Biotech conducts its clinical trials in collaboration with Merck, which supplies pembrolizumab for ongoing studies.